Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeeMore in patients with prior myocardial infarction
NCT00881075Phase 2Completed
- Sponsor
- Eagle Vision Pharmaceutical
- Start
- Jun 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of EVP-1001-1 in myocardial infarction (MI), sponsored by Eagle Vision Pharmaceutical. Primary endpoint: Safety and tolerance of SeeMore at 24 hours. Started Jun 2008; status: completed.
02
Drugs
EVP-1001-1
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00881075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881075.